Expert Discusses GLP-1 Receptor Agonists for Treatment of Diabetes
March 18th 2022Andrew Bzowyckyi, PharmD, BCPS, CDCES, associate professor at Pacific University Oregon and clinic pharmacist at Legacy Medical Group discusses the differences in GLP-1 receptor agonists and insulin for the management of diabetes.
Watch
Expert Discusses Pathways of Pharmacist Payment for Patient Services
March 18th 2022Melissa Somma McGivney, PharmD, FCCP, FAPhA, professor and associate dean for community partnerships at the University of Pittsburgh School of Pharmacy, gives a brief overview of the best practices when it comes to billing in a pharmacy.
Watch
Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses her presentation at the Society of Gynecologic Oncology 2022 annual meeting on the phase 2 trial of maintenance niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.
Watch
Overview of Key Developments in the Field of Gynecologic Oncology at the SGO Annual Meeting
March 17th 2022S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses some key developments in the field of gynecologic oncology that will be on the agenda at the SGO 2022 annual meeting.
Watch
Pharmacy Technicians Step Up During, After the COVID-19 Pandemic
February 18th 2022Pharmacy technicians are continuing to prove their worth as pharmacies shift their focus to the future, according to Jessica Langley-Loep, executive director of education and advocacy at the National Healthcareer Association.
Watch
Next Steps in Assessing BOVen Therapy in Patients With Previously Untreated CLL
December 23rd 2021Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses next steps in the research assessing zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.
Watch
Safety, Efficacy of BOVen Therapy in Patients With Previously Untreated CLL
December 22nd 2021Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses trial results showing the safety and efficacy of zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.
Watch
Assessing Adverse Events From BOVen Therapy in Patients With Previously Untreated CLL
December 21st 2021Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses the adverse events experienced by patients with previously untreated chronic lymphocytic leukemia when treated with zanubrutinib, obinutuzumab, and venetoclax.
Watch